Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a clinical-stage cell therapy company developing multi-antigen targeted T-cell therapies, with a focus on its MAR-T platform and lead candidates such as MT-601 and MT-401. The company does not yet sell approved products and currently funds development through grants, equity financing, and collaborations with research and manufacturing partners.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical-stage MAR-T and OTS cell therapies being developed for AML, MDS, and other cancers.
Government and institutional grants that fund qualifying R&D and clinical trial activity.
Technology transfer, process development, and outsourced cGMP manufacturing support for pipeline programs.
Products
Reported · share of revenue- Cancer Prevention and Research Institute of Texas Acute Myeloid Leukemia25.4 %
- National Institutes of Health Small Business Innovation Research for Lymphoma Grant18.7 %
- Cprit Pancreatic Grant16.2 %
- National Institutes of Health Small Business Innovation Research13.3 %
- National Institutes of Health Small Business Innovation Research for Pancreatic Cancer12.0 %
- Other14.3 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Marker Therapeutics' direct economic counterparties are not commercial customers but grant agencies, clinical investigators, and manufacturing partners that support development of its product candidates. The eventual end users are patients with difficult-to-treat cancers such as AML and MDS, while the near-term buyers of services are public funding bodies and CDMOs that enable clinical execution.
CPRIT, FDA, and NIH fund specific development programs and reimburse qualifying research costs.
Academic and clinical centers run studies for MT-401 and MT-601 and generate the data needed for approval.
Cellipont and other third parties provide technology transfer, process development, and cGMP manufacturing.
If approved, hospitals and cancer centers would purchase and administer the therapies.
Strategy
The company is focused on advancing MT-601 and MT-401 through clinical development while preserving cash through outsourced manufacturing and grant funding. Near-term priorities are technology transfer, patient enrollment, and generating early safety/efficacy data that can support additional financing, partnerships, and eventual regulatory filings.
The lead program needs manufacturing scale-up and clinical data to validate the MAR-T platform.
The off-the-shelf AML program could broaden the platform and address rapidly progressing diseases.
The company has no commercial revenue and must fund operations through external capital and grants.
Third-party cGMP manufacturing reduces capital intensity and supports commercial scalability if approved.
Geography
Marker Therapeutics is headquartered in the United States and its development, manufacturing, and regulatory activities are centered there. The company previously operated cGMP facilities in Houston, Texas, and now relies on U.S.-based third-party manufacturing and U.S. clinical/regulatory infrastructure, making it highly exposed to FDA, NIH, and U.S. capital market conditions.
Risks
Marker Therapeutics faces classic clinical-stage biotech risks: program failure, regulatory delay, and dependence on external capital before any product revenue exists. Its business is also exposed to government funding disruptions, FDA review delays, and the risk that outsourced manufacturing or clinical execution does not scale as planned.
The company has no approved products, so negative trial results would impair the core asset base.
Operations are funded through equity, debt, and grants, with no recurring product revenue.
Exposure: Near-term operating runway and dilution risk
FDA review timing and NIH/FDA grant administration can be slowed by staffing, budget, or shutdown issues.
The company relies on third parties for cGMP manufacturing and technology transfer.
ATM and other equity raises can materially dilute existing shareholders.
Exposure: Common stock holders
Accounting
Judgemental itemsRevenue is recorded only as qualifying costs are incurred, so timing of clinical spend drives reported revenue.
Impact: Quarterly revenue volatility and deferred revenue balances
Grant proceeds received in advance can sit on the balance sheet until eligible costs are incurred.
Impact: Liquidity presentation and liability recognition
Limited cash and recurring losses require management to assess whether operations can continue.
Impact: Financial statement basis and investor risk perception
Equity-based compensation and share issuances affect operating expenses and dilution.
Impact: Net loss, share count, and per-share metrics
Similar listed companies
Publicly listed companies with a comparable business focus.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Perspective Therapeutics, Inc.
CATX · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
MacroGenics, Inc
MGNX · Pharmaceutical Preparations
MacroGenics is a U.S.
Last updated: 24/09/2026